Syndax pipeline update: Revuforj and Niktimvo catalysts to watch

Syndax Pipeline Update: Revuforj and Niktimvo Catalysts to Watch

Syndax Pharmaceuticals now anchors its commercial base on two FDA-approved oncology assets: Revuforj (revumenib), a menin inhibitor for relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a CSF-1R antagonist for chronic graft-versus-host disease. This Syndax pharmaceuticals news plan focuses on the company's approved assets and the next clinical catalysts that matter to analysts. It is built to support competitive benchmarking, FDA context, and investment-useful follow-up.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is medium for this topic, with revumenib and axatilimab most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Syndax's Commercial Base Now Rests on Two FDA-Approved Assets

Revuforj (revumenib) is indicated for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older. The same asset also carries approval for relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. These dual indications define the marketed footprint for the oral menin inhibitor.

Niktimvo (axatilimab-csfr) is an FDA-approved colony stimulating factor-1 receptor (CSF-1R)-blocking antibody indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Syndax Pharmaceuticals reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

The Revumenib Pipeline Adds Near-Term Catalyst Visibility

Beyond the approved indications, Syndax and its collaborators are advancing revumenib across several trial stages. A phase 3 trial sponsored by Syndax is recruiting patients with newly diagnosed AML and an NPM1 mutation to receive revumenib in combination with intensive chemotherapy.

A phase 2 trial sponsored by UNC Lineberger Comprehensive Cancer Center is not yet recruiting patients with newly diagnosed KMT2A-rearranged AML to receive revumenib, azacitidine, and venetoclax. The trial's not-yet-recruiting status means enrollment timelines remain unclear.

A phase 1 trial sponsored by Uma Borate is actively recruiting patients with relapsed or refractory FLT3-mutated AML and concurrent MLL-rearrangement or NPM1 mutation to receive SNDX-5613 and gilteritinib.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for this topic. Expect implications for pricing, access, and launch sequencing.

Niktimvo Expansion Trials in Chronic Graft-Versus-Host Disease

Axatilimab development extends beyond the approved relapsed setting. A phase 2 trial sponsored by Incyte Corporation is recruiting pediatric patients with chronic graft-versus-host disease after at least two prior lines of systemic therapy to compare axatilimab versus best available therapy. A phase 3 trial sponsored by Incyte is recruiting patients to evaluate axatilimab and corticosteroids as initial treatment for chronic graft-versus-host disease.

IntelligenceStrategic Takeaways▾

Revuforj (revumenib) is FDA-approved for relapsed or refractory acute leukemia with KMT2A translocation and for relapsed or refractory AML with susceptible NPM1 mutation, both in adult and pediatric patients 1 year and older. Niktimvo (axatilimab-csfr) is FDA-approved for chronic graft-versus-host disease after at least two prior lines of systemic therapy in eligible adult and pediatric patients. A phase 3 trial of r

What to Watch Next

The dual-asset approved portfolio and active pipeline create multiple readout opportunities over the near term. For equity analysts evaluating Syndax Pharmaceuticals stock, the key question is whether the ongoing trials can expand the addressable population beyond current labels. The phase 3 revumenib trial in newly diagnosed NPM1-mutated AML and the phase 2 trial of revumenib, azacitidine, and venetoclax in newly diagnosed KMT2A-rearranged AML represent the most visible clinical catalysts.

For business development teams, the pipeline demonstrates Syndax's focus on genetic subtypes of hematologic malignancy and GVHD. The reliance on partner-sponsored trials (UNC Lineberger, National Cancer Institute, Incyte) signals collaboration across academic and commercial sponsors.

IntelligenceEvidence Quality▾

Grounded in 2 regulatory sources.

Timeline of Approved Products and Visible Catalyst Points

Syndax's most recent corporate filings include an 8-K dated June 4, 2026, and earlier quarterly and annual reports. The next observable pipeline checkpoints are the recruiting and not-yet-recruiting clinical trials noted above, which will generate data readouts on a staggered timeline dependent on enrollment and protocol-specified follow-up periods.

Key Takeaways

• Revuforj (revumenib) is FDA-approved for relapsed or refractory acute leukemia with KMT2A translocation and for relapsed or refractory AML with susceptible NPM1 mutation, both in adult and pediatric patients 1 year and older.
• Niktimvo (axatilimab-csfr) is FDA-approved for chronic graft-versus-host disease after at least two prior lines of systemic therapy in eligible adult and pediatric patients.
• A phase 3 trial of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1-mutated AML is actively recruiting.
• Multiple partner-sponsored trials advance revumenib in combination regimens and axatilimab in pediatric and early-line GVHD settings, creating staggered data readouts.

Frequently Asked Questions

Related profiles

• axatilimab
• REVUFORJ
• NIKTIMVO
• Syndax Pharmaceuticals

Related coverage

• Tillomed Laboratories update: pipeline, melphalan and next catalysts
• Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update
• Manufacturing pipeline approvals: what the evidence confirms